Literature DB >> 6087750

Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats.

A W Zuardi, N A Teixeira, I C Karniol.   

Abstract

The pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol (delta 9-THC) and cannabidiol (CBD) on serum corticosterone levels in rats was studied in two experimental situations: simultaneous administration of the two cannabinoids, or administration of one followed by the other 24 hr later. Forty-five min after administration, both delta 9-THC (1, 2 and 4 mg/kg) and CBD (10, 30 and 60 mg/kg) induced a dose-dependent increase in corticosterone levels. The effect of the mixture delta 9-THC (2 mg/kg) with CBD (10, 30 and 60 mg/kg) did not differ significantly from that produced by CBD alone. We also observed that CBD (30 mg/kg), 24 hr after administration, potentiated the effect of delta 9-THC (2 mg/kg) even though it had no effect on corticosterone levels. This delayed interference of CBD with delta 9-THC effects was attributed to a pharmacokinetic interaction between the two cannabinoids.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6087750

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  12 in total

1.  Cortical 3 alpha-hydroxy-5 alpha-pregnan-20-one levels after acute administration of Delta 9-tetrahydrocannabinol, cocaine and morphine.

Authors:  A Chistina Grobin; Margaret J VanDoren; Linda J Porrino; A Leslie Morrow
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

2.  Cannabidiol-Δ9-tetrahydrocannabinol interactions on acute pain and locomotor activity.

Authors:  Stevie C Britch; Jenny L Wiley; Zhihao Yu; Brian H Clowers; Rebecca M Craft
Journal:  Drug Alcohol Depend       Date:  2017-04-15       Impact factor: 4.492

3.  Interaction between cannabidiol (CBD) and ∆(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids.

Authors:  Antonio Waldo Zuardi; Jaime Eduardo Cecílio Hallak; José Alexandre S Crippa
Journal:  Psychopharmacology (Berl)       Date:  2011-09-21       Impact factor: 4.530

4.  The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis.

Authors:  J M Jamontt; A Molleman; R G Pertwee; M E Parsons
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Effects of cannabidiol in animal models predictive of antipsychotic activity.

Authors:  A W Zuardi; J A Rodrigues; J M Cunha
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 6.  Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

Authors:  Douglas L Boggs; Jacques D Nguyen; Daralyn Morgenson; Michael A Taffe; Mohini Ranganathan
Journal:  Neuropsychopharmacology       Date:  2017-09-06       Impact factor: 7.853

7.  Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ(9) -tetrahydrocannabinol in Sprague-Dawley rats.

Authors:  Michael A Taffe; Kevin M Creehan; Sophia A Vandewater
Journal:  Br J Pharmacol       Date:  2015-01-23       Impact factor: 8.739

Review 8.  Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.

Authors:  Matthew N Hill; Patrizia Campolongo; Rachel Yehuda; Sachin Patel
Journal:  Neuropsychopharmacology       Date:  2017-07-26       Impact factor: 7.853

Review 9.  HPA Axis Interactions with Behavioral Systems.

Authors:  Amy E B Packard; Ann E Egan; Yvonne M Ulrich-Lai
Journal:  Compr Physiol       Date:  2016-09-15       Impact factor: 9.090

10.  Cannabidiol attenuates deficits of visuospatial associative memory induced by Δ(9) tetrahydrocannabinol.

Authors:  M Jerry Wright; Sophia A Vandewater; Michael A Taffe
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.